Form 4: Surgery Partners COO Acquires 77,736 Shares

Surgery Partners' COO and National Group President, Justin Robert Oppenheimer, acquired 77,736 shares of common stock through restricted stock awards.

Summary

• Justin Robert Oppenheimer, COO & National Group President of Surgery Partners, Inc. (SGRY), acquired 77,736 shares of common stock.
• The acquisition occurred on January 13, 2026, through restricted stock awards (RSAs).
• Each share was valued at $16.08 at the time of the grant.
• These RSAs are scheduled to vest in a single installment on the first anniversary of the grant date, which is January 13, 2027.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Mr. Oppenheimer beneficially owns 77,736 shares directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, even as compensation, generally signals confidence in the company's future prospects and aligns management's interests with shareholders. This is a moderately positive signal.

Positives

• Insider acquisition of 77,736 shares of common stock by a key executive, Justin Robert Oppenheimer, potentially signals management's confidence in the company's future performance.
• The grant of restricted stock awards aligns the interests of the COO with those of shareholders, as the value of his compensation is tied to the company's stock performance.

Negatives

• No explicit negative information is typically disclosed in a Form 4 filing, which primarily reports changes in beneficial ownership.

Risks

• No specific risks are detailed in this Form 4 filing, as it is a transactional report rather than a comprehensive risk disclosure document.

Future Outlook

The restricted stock awards granted to Justin Robert Oppenheimer are scheduled to vest in one installment on January 13, 2027, which is the first anniversary of the grant date. This indicates a future milestone for the executive's equity compensation.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing. The filing is a factual report of a transaction.

Industry Context

This Form 4 filing reports a standard insider transaction involving equity compensation. Such filings are common across all industries for publicly traded companies and do not, by themselves, provide specific insights into broader industry trends or competitive dynamics. They primarily serve to disclose changes in beneficial ownership by company insiders.

Comparison to Industry Standards

• Not applicable, as this filing is a standard insider transaction report (Form 4) and does not contain performance metrics or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock awards to a key executive aligns management's long-term interests with those of shareholders, potentially fostering decisions that enhance shareholder value.
• Employees: This type of equity compensation is a standard practice for executive retention and motivation, potentially impacting overall employee morale and commitment.

Next Steps

• Vesting of the 77,736 restricted stock awards on January 13, 2027.

Key Dates

Keywords

Surgery Partners, SGRY, Justin Oppenheimer, Restricted Stock Awards, Insider Trading, Form 4, Equity Compensation, Executive Compensation